Why Celcuity Stock Popped Today

Core Insights - Celcuity reported a narrower-than-expected net loss for Q4 2025, leading to a stock price increase of over 4% [1] Financial Performance - The company did not report any revenue for Q4 or the full year 2025 [2] - Operating expenses rose to over $49 million from over $36 million in Q4 2024 [2] - The net loss under GAAP increased to $38.4 million ($0.73 per share) from $32.3 million the previous year, which was better than analysts' expectations of a $1.05 per share loss [3] Clinical Developments - Celcuity anticipates topline results from a phase 3 clinical trial of gedatolisib for advanced breast cancer, expected in Q2 [4] Cash Position - The company had cash and cash equivalents of nearly $166 million at the end of the quarter, significantly up from $22.5 million at the end of 2024, providing a solid financial foundation for future operations [6] Market Sentiment - The positive financial update and upcoming trial results contribute to a bullish outlook for the company [7]